Donald N Forthal

List of Publications by Year
in descending order

65 papers	4,850 citations	218381 26 h-index	128067 60 g-index
68 all docs	68 docs citations	68 times ranked	5256 citing authors

#	Article	IF	Citations
1	Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2023, 76, e477-e486.	2.9	29
2	Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. Journal of Virology, 2022, 96, JVI0168921.	1.5	0
3	How do I implement an outpatient program for the administration of convalescent plasma for <scp>COVID</scp> â€19?. Transfusion, 2022, , .	0.8	13
4	Association between vaccine preventable diseases in children and improved sanitation following a nationwide sanitation campaign in India: an ecological analysis. BMJ Open, 2022, 12, e052937.	0.8	0
5	IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men. Virulence, 2022, 13, 757-763.	1.8	0
6	Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.. Drug Discovery Today, 2021, 26, 593-603.	3.2	52
7	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccineâ€"Induced Anti-V2 Antibodies Alone. Journal of Immunology, 2021, 206, 1266-1283.	0.4	8
8	COVID-19: An unprecedented challenge and an opportunity for change. Advanced Drug Delivery Reviews, 2021, 171, 48-49.	6.6	0
9	Adaptive immune responses to SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 172, 1-8.	6.6	6
10	Diverse antiviral IgG effector activities are predicted by unique biophysical antibody features. Retrovirology, 2021, 18, 35.	0.9	7
11	CD46 Genetic Variability and HIV-1 Infection Susceptibility. Cells, 2021, 10, 3094.	1.8	3
12	306. Association of Antibiotic Use and Development Secondary Infection from Clostridium difficile, Multidrug-Resistant Bacteria, and Candida in Hospitalized Patients with History of COVID-19. Open Forum Infectious Diseases, 2021, 8, S259-S260.	0.4	0
13	Infection prevention strategies are highly protective in COVID-19 units while main risks to healthcare professionals come from coworkers and the community. Antimicrobial Resistance and Infection Control, 2021, 10, 163.	1.5	6
14	Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. Aids, 2020, 34, 25-32.	1.0	9
15	Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs, 2020, 80, 1267-1292.	4.9	208
16	Authorsâ€™ Reply to Vrachatis et al. â€œPharmaco-Immunomodulatory Therapy in COVID-19â€• Drugs, 2020, 80, 1501-1503.	4.9	8
17	Impact of T _h 1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	30
18	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. Journal of Virology, 2020, 94, .	1.5	8

#	Article	IF	Citations
19	Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. Journal of Pediatrics, 2020, 223, 183-185.	0.9	15
20	Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. Journal of Virology, 2019, 93, .	1.5	12
21	Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. Journal of Virology, 2019, 93, .	1.5	25
22	Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. Journal of Virology, 2019, 93, .	1.5	13
23	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. Journal of Virology, 2018, 92, .	1.5	24
24	Antibody-dependent cellular cytotoxicity in HIV infection. Aids, 2018, 32, 2439-2451.	1.0	67
25	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nature Medicine, 2018, 24, 847-856.	15.2	65
26	Blocking HIV-1 replication: are Fcâ€“FcÎ³ receptor interactions required?. Journal of Clinical Investigation, 2018, 129, 53-54.	3.9	4
27	Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathogens, 2017, 13, e1006793.	2.1	20
28	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. Journal of Immunology, 2016, 197, 2726-2737.	0.4	34
29	Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. Journal of Virology, 2016, 90, 8487-8495.	1.5	7
30	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nature Medicine, 2016, 22, 762-770.	15.2	197
31	Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Molecular Immunology, 2016, 70, 94-103.	1.0	12
32	Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. Journal of Virology, 2016, 90, 4133-4149.	1.5	22
33	HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS ONE, 2016, 11, e0160341.	1.1	7
34	A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS ONE, 2015, 10, e0125581.	1.1	14
35	Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. PLoS ONE, 2015, 10, e0133509.	1.1	0
36	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens, 2015, 11, e1005042.	2.1	145

#	Article	IF	Citations
37	Enhanced In Vitro Transcytosis of Simian Immunodeficiency Virus Mediated by Vaccine-Induced Antibody Predicts Transmitted/Founder Strain Number After Rectal Challenge. Journal of Infectious Diseases, 2015, 211, 45-52.	1.9	11
38	Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine, 2015, 33, 2086-2095.	1.7	63
39	Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine, 2014, 32, 6527-6536.	1.7	9
40	Modulation of RAS Pathways as a Biomarker of Protection against HIV and as a Means to Improve Vaccine Efficacy. AIDS Research and Human Retroviruses, 2014, 30, A99-A99.	0.5	2
41	Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIV_{mac251} Acquisition. AIDS Research and Human Retroviruses, 2014, 30, A64-A65.	0.5	3
42	Chemically Modified Peptides Based on the Membrane-Proximal External Region of the HIV-1 Envelope Induce High-Titer, Epitope-Specific Nonneutralizing Antibodies in Rabbits. Vaccine Journal, 2014, 21, 1086-1093.	3.2	13
43	Functions of Antibodies. Microbiology Spectrum, 2014, 2, AID-0019-2014.	1.2	139
44	Functions of Antibodies. Microbiology Spectrum, 2014, 2, 1-17.	1.2	50
45	The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells. PLoS Pathogens, 2013, 9, e1003776.	2.1	83
46	Antibody-Dependent Cell-Mediated Virus Inhibition Antibody Activity Does Not Correlate With Risk of HIV-1 Superinfection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 31-33.	0.9	20
47	A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1. PLoS ONE, 2013, 8, e72054.	1.1	20
48	Antibody-Dependent Enhancement and the Risk of HIV Infection. Current HIV Research, 2013, 11, 421-426.	0.2	31
49	Association of FcÎ³ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood, 2012, 120, 2836-2842.	0.6	57
50	In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. International Journal of Antimicrobial Agents, 2012, 40, 354-360.	1.1	6
51	IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. Aids, 2011, 25, 2099-2104.	1.0	24
52	Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce Î²-chemokines. Journal of Experimental Medicine, 2010, 207, 763-776.	4.2	51
53	Fc-Glycosylation Influences FcÎ³ Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. Journal of Immunology, 2010, 185, 6876-6882.	0.4	138
54	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathogens, 2009, 5, e1000433.	2.1	475

#	Article	IF	Citations
55	Fc receptor-mediated antiviral antibodies. Current Opinion in HIV and AIDS, 2009, 4, 388-393.	1.5	130
56	Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. Journal of Immunology, 2007, 178, 6596-6603.	0.4	169
57	FcÎ³RIIa Genotype Predicts Progression of HIV Infection. Journal of Immunology, 2007, 179, 7916-7923.	0.4	124
58	Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007, 449, 101-104.	13.7	828
59	Rhesus Macaque Polyclonal and Monoclonal Antibodies Inhibit Simian Immunodeficiency Virus in the Presence of Human or Autologous Rhesus Effector Cells. Journal of Virology, 2006, 80, 9217-9225.	1.5	87
60	Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 2042-2049.	1.5	43
61	Placeboâ€Controlled Phase 3 Trial of a Recombinant Glycoprotein 120 Vaccine to Prevent HIVâ€1 Infection. Journal of Infectious Diseases, 2005, 191, 654-665.	1.9	852
62	Relationship between Antibody-Dependent Cellular Cytotoxicity, Plasma HIV Type 1 RNA, and CD4+Lymphocyte Count. AIDS Research and Human Retroviruses, 2001, 17, 553-561.	0.5	76
63	Antibody from Patients with Acute Human Immunodeficiency Virus (HIV) Infection Inhibits Primary Strains of HIV Type 1 in the Presence of Natural-Killer Effector Cells. Journal of Virology, 2001, 75, 6953-6961.	1.5	208
64	Sex-Associated Differences in the Antibody-Dependent Cellular Cytotoxicity Antibody Response to Measles Vaccines. Vaccine Journal, 2000, 7, 111-113.	2.6	22
65	In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. Journal of Immunological Methods, 1998, 220, 129-138.	0.6	34